What happened with ADMA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ADMA Biologics, Inc.’s main products, ASCENIV and BIVIGAM, provide antibodies by intravenous infusion to patients with primary immunodeficiency. ASCENIV brings in most of the company’s revenue, with BIVIGAM the next-largest product. It also sells Nabi-HB for specified hepatitis B exposures. Sales are overwhelmingly in the United States, through distributors, wholesalers and specialty pharmacies that supply infusion providers. BioCare and Priority Healthcare Distribution, known as CuraScript, together account for most revenue, making these customer relationships central to the business.
ADMA collects plasma through its ADMA BioCenters subsidiary and buys additional plasma from outside suppliers, then separates and purifies it at its Boca Raton, Florida facility to make its medicines. ASCENIV uses patented screening and carefully selected plasma pools that combine ordinary plasma with plasma containing high levels of antibodies that neutralize respiratory syncytial virus (RSV). Suitable high-antibody plasma is uncommon, and ADMA relies on third-party purchases for this supply. Selling plasma not used in its own medicines provides a smaller revenue stream.
Production depends on the Boca Raton facility, with no alternative manufacturing facility arranged if it is lost. ADMA and its suppliers must maintain FDA approvals and manufacturing compliance. ASCENIV is approved for primary immunodeficiency; marketing it for other indications requires additional successful clinical trials and FDA approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ADMA’s results hinge on ASCENIV adoption, high-titer plasma supply and manufacturing yields; CSL Behring is another important immunoglobulin competitor to watch beyond this list.
ADMA depends on Grifols for high-titer RSV plasma used in ASCENIV and hepatitis B plasma used in Nabi-HB, even as both sell plasma-derived immunoglobulin medicines to healthcare providers. Watch the volume and price of Grifols’ ASCENIV plasma supply: the agreement requires at least 35,000 liters annually, with per-liter pricing that rises with volume and a minimum annual increase.
Takeda competes for the patients and treatment providers buying ADMA’s immune globulin medicines through its own plasma-derived therapies. Its plasma-derived therapy sales are the relevant business to watch for ADMA, rather than its broader prescription-drug portfolio.
Fed Interest Rate Decision
ADMA’s Fed interest-rate decision matters because it can shift the cost of interest on its $74.1 million term debt if that debt reprices, changing the cash left to fund its operations.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is higher than expected, interest on any debt that reprices may rise, leaving ADMA less cash from operations to support plasma collection and immune-globulin manufacturing.
If it comes in below expectations
If the policy rate is lower than expected, interest on any debt that reprices may fall, leaving ADMA more cash from operations to support plasma collection and immune-globulin manufacturing.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report will show how providers and patients are buying its plasma-derived therapies, offering ADMA a read on demand in the immune globulin market they share.
Focus on Takeda’s plasma-derived therapy sales and volume, not its broader drug portfolio. Growth in both would indicate firm provider and patient demand for these treatments, supporting demand in the market for ADMA’s ASCENIV and BIVIGAM. Weakness in both would suggest the shared market is cooling, but would not establish that ADMA sales are falling.
ADMA Biologics, Inc. earningsThis company
ADMA Biologics’ report will show whether its yield-enhancement process turns the same plasma into more immune globulin it can sell and distributors and providers will use.
Read ASCENIV and BIVIGAM sales and product volumes alongside gross margin. Rising sales and volume with improving margin would show that the extra output from the yield-enhancement process is being sold and leaving more gross profit per unit. Weak volume or sales, or no margin improvement, would point to a constraint in plasma supply, production, quality, or demand; revenue alone would not prove the process is working.
